GEHC Stock Analysis — GE Healthcare
Sector: Healthcare
AI Verdict
GE Healthcare trades at 12x next year's earnings while analysts expect 22% EPS growth—this is cheap for the growth on offer if its entrenched hospital relationships keep competitors at bay.
Competitive Moat
GE Healthcare dominates in medical imaging and diagnostics, leveraging decades of installed equipment and service contracts that create high switching costs for hospitals. Its scale and integration with hospital IT systems make it difficult for new entrants to displace its footprint.
Summary
GE Healthcare's extremely low RSI of 18.5 signals deep oversold territory after a -10.96% one-year return.
Where It Stands
Shares have dropped -10.96% over the past year, trade at 12.0x forward earnings versus the sector median of 22x, and an RSI of 18.5 points to extreme oversold conditions.
Key Metrics
- RSI: 18.5 — Oversold
- Trailing P/E: 14.7x
- Forward P/E: 12.0x
- PEG Ratio: 0.68
- Earnings Growth: +0.2%
- Revenue Growth: +0.0%
- Dividend Yield: 0.00%
- 1-Year Return: -10.96%
- 52-Week High: $89.77
- 52-Week Low: $58.75
Analyst Consensus
18 Buy · 9 Hold · 1 Sell (28 analysts)
Bull Case
Analysts expect 22.0% forward EPS growth, which is unusually high for a healthcare equipment name trading at just 12.0x forward earnings.
Bear Case
If the P/E reverts to the sector median of 22x only with flat growth, the stock could stay stuck in value trap territory despite the low RSI.
Catalyst to Watch
Watch for upcoming product launches or hospital contract wins that could confirm whether the 22.0% EPS growth forecast is achievable.